Mucosis’s lead program FluGEM® seeks to develop a new innovative influenza vaccine that can be administered to humans by a simple spray in the nose. The program is particularly directed at achieving better protection against seasonal influenza in vulnerable people, such as elderly and children. Mucosis also runs research programs aimed at the development of intranasal vaccines to prevent respiratory syncytial virus and pneumococcal related diseases, and an oral vaccine to prevent bacterial diarrhea.
The development phases of the Mucosis programs
